COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN

被引：0
|
作者：
Clements, K. M. [1 ]
Hulbert, E. M. [2 ]
Panchmatia, H. R. [1 ]
Eriksson, M. [3 ]
Wittrup-Jensen, K. U. [4 ]
Nilsson, J. [5 ]
Weinstein, M. C. [6 ]
机构：
[1] OptumInsight, Cambridge, MA USA
[2] OptumInsight, Eden Prairie, MN USA
[3] Bayer AB, Solna, Sweden
[4] Bayer Pharma AG, Berlin, Germany
[5] OptumInsight, Stockholm, Sweden
[6] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1168
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A506 / A506
页数：1
相关论文
共 50 条
  • [21] Intravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration
    Cundy, Olivia
    Shah, Mital
    Downes, Susan M.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2018, 13 (02) : 75 - 86
  • [22] Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept
    Hatz, Katja B.
    Cedro, Luca
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [23] Intravitreal Ziv-Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    de Oliveira Dias, Joao Rafael
    Xavier, Camilla Oliveira
    Novais, Eduardo Amorim
    Maia, Andre
    Moraes, Nilva
    Farah, Michel Eid
    Rodrigues, Eduardo Buechele
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [24] Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
    Rachel Hui Fen Lim
    Bhaskar Gupta
    Peter Simcock
    International Journal of Ophthalmology, 2017, (03) : 423 - 426
  • [25] Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    Rush, Sloan W.
    CLINICAL OPHTHALMOLOGY, 2022, 16 : 4041 - 4046
  • [26] INTRAVITREAL AFLIBERCEPT FOR TREATMENT-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Chang, Andrew A.
    Li, Haitao
    Broadhead, Geoffrey K.
    Hong, Thomas
    Schlub, Timothy E.
    Wijeyakumar, Wijeyanthy
    Zhu, Meidong
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 : 52 - 52
  • [27] Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration and Pigment Epithelial Detachment
    Felix, Armada
    Cidad, Pino
    Pastora, Natalia
    Manzano, Beatriz
    Rosa, Irene
    Del Barrio, Zurine
    Mediero, Soraya
    Capote, Maria
    DAnna, Oriana
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [28] Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
    Lim, Rachel Hui Fen
    Gupta, Bhaskar
    Simcock, Peter
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (03) : 423 - 426
  • [29] Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
    Ferrante, Nicola
    Ritrovato, Daniela
    Bitonti, Rossella
    Furneri, Gianluca
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [30] The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
    Musial-Kopiejka, Magdalena
    Polanowska, Katarzyna
    Dobrowolski, Dariusz
    Krysik, Katarzyna
    Wylegala, Edward
    Grabarek, Beniamin Oskar
    Lyssek-Boron, Anita
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
12345